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publish or writing of the manuscript.
Abstract
Improvement	of	sleep	is	a	central	treatment	goal	for	patients	in	a	manic	state.	Blue-
blocking	 (BB)	glasses	as	adjunctive	 treatment	hasten	overall	 recovery	 from	mania.	
This method is an evolvement from dark therapy and builds on the discovery of the 
blue-light-sensitive	retinal	ganglion	cell	that	signals	daytime	to	the	brain.	We	report	
effects	of	adjunctive	BB	glasses	on	actigraphy-derived	sleep	parameters	for	manic	
inpatients	 as	 compared	 to	 placebo.	 Hospitalized	 patients	 with	 bipolar	 disorder	 in	










logical treatment and showed significantly higher sleep efficiency and more consoli-
dated	sleep	as	compared	to	the	placebo	group.	Our	findings	suggest	sleep-promoting	
effects	through	deactivating	mechanisms.	Adjunctive	BB	glasses	seem	to	be	useful	
for improving sleep for manic patients in the hospital setting.
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tion	 for	 going	 to	bed	diminishes.	At	 the	 transition	 to	 frank	mania,	
activation,	 irritability	 and	 grandiosity	 rise	 even	 further.	Grandiose	
psychosis	usually	interferes	with	the	patients'	insight	and	ability	to	
comply	with	 the	 treatment.	Even	with	good	cooperation	 from	 the	
patient,	pharmacological	restoring	of	sleep	during	mania	can	be	chal-
lenging	and	may	require	high	doses	of	antipsychotics,	sedatives	and	
hypnotics. This unsatisfactory clinical shortcoming may arise from 
an	incomplete	understanding	of	the	mania-sustaining	processes.






irregular	 to	 regular	 sleep	 concomitant	 with	 stabilization	 of	 mood	






for	 the	use	of	blue-blocking	 (BB)	 glasses	 as	 a	means	of	 creating	 a	
virtual	darkness	for	the	brain	(Kayumov	et	al.,	2005;	Phelps,	2008).
Light	 at	 night	may	 disrupt	 circadian	 rhythms	 and	 inhibit	 sleep	
Esaki	et	al.,	2019;	Green,	Cohen-Zion,	Haim,	&	Dagan,	2017).	The	
retinal daylight receptors project directly to the circadian master 





a daylight signal and suppresses melatonin production via the ip-
RGC-SCN	 projections.	 Conversely,	 light	 depleted	 of	 wavelengths	








the	change	 in	 sleep	was	a	 replication	of	 the	preceding	dark-therapy	




(YMRS)	 outcomes	 after	 intervention	 with	 adjunctive	 BB	 glasses,	 as	
compared	 to	 placebo	 (clear-lensed	 glasses)	 (Henriksen	 et	 al.,	 2016;	
Young,	Biggs,	Ziegler,	&	Meyer,	1978).
Here	we	present	the	sleep	outcomes	from	the	same	trial,	as	mea-












single-blinded	 trial,	 recruiting	 patients	 from	 five	 hospitals	 in	 the	
southwest	of	Norway,	latitude	58–59′N,	in	the	time	period	February	
2012	 to	February	2015	 (Henriksen	et	 al.,	 2016).	The	 trial	 is	 regis-
tered with Clini calTr ials.gov: NTC01818622.
Eligible	participants	were	patients	in	hospital	with	BD	in	a	manic	
phase,	 aged	18–70	years.	Adherence	 to	 the	allocated	 intervention	
and	valid	actigraphy	recordings	for	night	1	and	night	5	qualified	pa-
tients for inclusion in the statistical analyses of difference between 
the	groups.	For	the	description	of	nights	with	interrupted	sleep,	all	





The	 Regional	 Ethical	 Committee	 in	 Norway	 (REK	 registration	
2011/1668)	 approved	 the	 procedures,	 which	 were	 in	 accordance	
with	the	Helsinki	Declaration.	All	patients	included	in	the	study	pro-
vided written informed consent.
2.3 | Randomization and masking
The	 included	 patients	were	 randomly	 assigned	 to	 BB	 glasses	 or	
clear	(placebo)	glasses,	by	a	manual	draw	performed	by	secretaries	
     |  3 of 11HENRIKSEN Et al.
not	otherwise	involved	in	the	trial.	All	participants	received	identi-
cal	information	about	the	purpose	of	the	study,	which	was	testing	
the effectiveness of different glasses in reducing manic symptoms. 
The	included	patients	had	no	previous	knowledge	of	effects	of	BB	
glasses. No patients observed glasses of different color to their 
own.
2.4 | Procedures











a	previous	publication	 from	 the	 trial	 (Henriksen	et	al.,	2016).	All	
patients	received	treatment	as	usual	(TAU),	individualized	accord-
ing	 to	 daily	 symptom	 levels,	 acceptance	 by	 patients,	 best	medi-
cal	 judgement	 and	 law	 restrictions.	 The	 pharmacological	 TAU	 is	
shown in Table 1. Participants and nursing staff were instructed 
that neither type of glasses could be taken off unless turning out 
the	light	at	bedtime.	In	the	case	of	wake	before	08:00	hours,	the	
glasses should be put on. The participants could choose between 





supporting data from daily nurse reports on sleep and wakefulness. 
All	 participants	 wore	 an	 actigraph	 device	 (Actiwatch	 Spectrum,	
Philips	Respironics	Inc.)	on	the	wrist,	left	or	right	according	to	per-
sonal	preference.	Data	were	recorded	in	30-s	epochs.	Start	and	end	









Habitual	 morningness	 or	 eveningness	 was	 assessed	 by	




items describing actual daily behaviour and 14 items referring to 
preferred	 timing	 in	 a	 self-regulated	 environment	 (i.e.,	 preferred	
time of sleep and what time of day the person feels most compe-
tent	to	perform	demanding	tasks).	MEQ	scores	between	59	and	86	
indicate	morning	 types,	42–58	 indicates	neither	 type	and	16–41	
indicates evening types.
The	global	seasonality	score	(GSS)	derives	from	sub-scores	in	
the	 Seasonal	 Pattern	 Assessment	 Questionnaire	 (SPAQ),	 which	
was	 originally	 made	 to	 assess	 seasonal	 affective	 disorder	 (SAD)	
(Melrose,	 2015).	 The	 GSS	 measures	 seasonal	 variations	 in	 the	








The primary outcomes were sleep efficiency (percentage sleep dur-
ing	the	main	rest	interval)	and	motor	activity	during	sleep	intervals.	
The	secondary	outcomes	were	 total	 sleep	 (hours)	during	 the	main	
rest	interval,	wake	after	sleep	onset	(minutes),	number	of	wake	epi-




through to night 5 were included.
2.8 | Statistical analyses
To	 characterize	 the	 sample,	 descriptive	 statistical	 methods	 were	
used.	 The	 effect	 of	 BB	 glasses	 at	 night	 5	was	 assessed	 using	 the	
ANCOVA;	that	is,	the	linear	regression	for	the	outcome	variable	at	




of the allocation as described in the trial profile in a previous publi-
cation	(Henriksen	et	al.,	2016).	At	night	5,	the	integrity	of	the	RCT	
design	was,	however,	still	sufficiently	maintained.
In	 the	 graphical	 presentation,	 we	 used	 the	 raw	 data	 for	 each	
patient	and	the	mean	(95%	confidence	 interval	 [CI])	at	night	1	and	
night	 5.	 Sleep	 efficiency,	 activity,	 wake	 after	 sleep	 onset,	 wake	
bouts	and	sleep	fragmentation	 index	were	 log-transformed	before	
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the	regression	analysis	and	computation	of	mean	(95%	CI).	The	sig-






protocol and six patients withdrew consent. One patient was ex-
cluded	due	to	withdrawal	symptoms	and	one	patient's	actigraphy	
recording	 failed.	 In	 the	 BB	 group,	 one	 patient	 dropped	 out	 after	





Clinical	 characteristics	 of	 the	 current	 episode,	 previous	 medical	
history and measures of seasonality and morningness/eveningness 
TA B L E  1   Individual	medications	for	patients	assigned	to	blue-blocking	glasses	or	clear	glasses	(placebo)
Patient













2a Quetiapine	200.0    
































 Lithium	sulphate	84.0  
12 Olanzapine	20.0 Valproate	562.6   
13 Olanzapine	15.0    




Valproate	450.0   
16 Olanzapine	25.0 Lamotrigine	200.0 Lithium	sulphate	192.6 Clonazepam	0.9




19 Risperidone 0.6 Lamotrigine	162.5 Lithium	sulphate	120.8 Alimemazine	3.75,	Mirtazapine	24.4b
20 Olanzapine	15.0 Valproate	600.0   
aPatients	2	and	5	were	administered	ibuprofen	250	mg/day.	Ibuprofen	may	affect	melatonin	production.	
bSedation	is	a	recognized	side-effect	of	the	antidepressant	mirtazapine	
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are shown in Table 2. The placebo group was somewhat older (mean 
48.8	years	vs.	43.9	years)	and	had	a	modestly	higher	mean	YMRS	total	
score	at	the	start	of	the	intervention	(26.8	vs.	23.9).	The	placebo	group	
scored	on	average	as	more	morning	 type	 than	 the	BB	group	 (MEQ:	
60.4	±	5.8	vs.	52.4	±	14.8,	respectively).	The	data	on	seasonality	were	
similar	 across	 the	 groups;	mean	GSS	 scores	were	 under	 the	 cut-off	
for	sub-SAD	for	both	the	placebo	and	the	BB	groups	(8.1	vs.	7.3,	re-
spectively).	Approximately	the	same	proportion	of	patients	in	the	two	







ficiency was significantly higher as compared to the placebo group 





The	 BB	 group	 showed	 lower	 activity	 counts	 per	 epoch	 (one	
epoch	=	30	 s)	 during	 the	main	 sleep	 interval	 at	 night	5	 compared	
to the placebo group (p	=	 .007).	 In	 the	BB	group,	 the	mean	activ-
ity	 during	 the	main	 sleep	 interval	 declined	 from	night	 1	 (20.0;	CI,	
9.1–30.9)	to	night	5	(11.7;	CI,	5.6	–	17.8),	whereas	the	placebo	group's	








F I G U R E  1   Trial profile
Assessed for eligibility (n = 40)
Excluded  (n = 8)
Did not meet inclusion criteria (n =3)
Declined to participate (n = 3)
Knowledge of blue-blockers (n = 2)
Analysed for actigraphy sleep outcomes (n =10)
Excluded from analysis (n = 1)
Withdrawal symptoms at start of intervention (n = 1)
Missing actigraphy recordings night 1 or 5 
(n = 2)
Allocated to BB-glasses (n =18) 
Received allocated intervention (n = 13)
Did not receive allocated intervention (n = 5)
Withdrew consent at first night (n = 3)
Unable to adhere to protocol from first night (n = 2)
Missing actigraphy recording (n = 1)
Allocated to clear glasses (placebo) (n =14)
Received allocated intervention (n = 11)
Did not receive allocated intervention (n =3)
Withdrew consent at first night (n = 3)




Randomized (n = 32)
Enrollment
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For	 the	 secondary	 outcome	 measures	 total	 sleep	 time,	 sleep	
maintenance,	 sleep	 fragmentation	 index	 and	 wake	 bouts,	 the	 BB	
group	 improved	 and	 the	 placebo	 group	worsened,	 but	 the	 differ-
ences	were	not	statistically	significant	in	this	sample	(Figure	3,	Table	
S1).
Descriptively,	 there	were	 fewer	 nights	 of	 biphasic	 or	 polypha-
sic	sleep	in	the	BB	group	as	compared	to	the	placebo	group,	when	
counting number of nights with one or more periods of active wake 
for	30	min	or	longer.	During	the	first	five	nights	of	actigraphy	mon-
itoring,	 29.6%	 (16/54)	 of	 valid	 night	 recordings	 for	 the	 BB	 group	




this without pursuing statistical testing.
We	also	observed	that	several	patients	 in	both	groups	showed	
irregular	sleep	timing	during	the	intervention.	High	day-to-day	vari-
ability	 of	 the	 length	 of	 the	 sleep	 interval,	 centred	 on	 a	 relatively	
stable	mid-sleep	 time,	was	 a	 characteristic	 sleep–wake	 pattern	 in	
several	patients,	as	shown	in	data	on	sleep	outcomes	for	the	full	7	







In	 this	 paper,	 we	 present	 data	 from	 the	 first	 study	 on	 change	 in	
actigraphy-derived	 sleep	 outcomes	 and	 sleep	 patterns	 during	 in-
tervention	with	BB	glasses	 for	BD	patients	 in	a	manic	episode	as	
















has	 recently	 been	 suggested	 that	 the	 48-hr-like	 rhythm	 of	 inter-
rupted sleep in bipolar disorder might reflect an amplified dopamine 
tone,	as	a	footprint	of	a	pathologically	prolonged	dopamine	ultradian	
oscillator	(DUO)	rhythm	(Blum	et	al.,	2014).	In	mice,	a	similar	48-hr	




pothesized	 that	 the	BB	 intervention	may	decrease	dopamine	 tone	
(Henriksen	et	al.,	2016).	The	multiple	examples	of	48-hr-like	activity	
patterns in this sample are interesting in relation to the theory of 
DUO-influenced	sleep	disturbance	in	mania	(Blum	et	al.,	2014).	More	
research is needed to establish whether the rhythm of motor activity 
bursts can serve as a proxy for dopamine tone in humans.
It	 is	 also	 of	 note	 that	 during	 the	 first	 five	 nights	 the	 placebo	
group's	sleep	worsened	on	all	outcomes	related	to	activated	sleep.	
Our	findings	add	to	the	growing	literature	on	poor	sleep	quality	for	
TA B L E  2   Characteristics of patients with mania assigned to 
blue-blocking	(BB)	glasses	or	placebo	glasses	(mean/SD)








































bWithout	patient	with	extreme	value	of	535	days,	n = 9. 
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hospitalized	patients,	and	how	the	hospital	environment	may	even	
worsen	 sleep	 (Horne,	 Hay,	Watson,	 &	 Anderson,	 2018;	 Lei	 et	 al.,	






the placebo group was not.
The placebo group received more intensive pharmacological treat-
ment	than	the	BB	group,	as	reported	in	a	previous	paper	from	the	trial	
and	shown	in	Table	1	(Henriksen	et	al.,	2016).	The	design	was	strictly	
F I G U R E  2  Sleep	efficiency	and	motor	





the placebo group (n	=	10)	are	shown,	and	
95%	confidence	interval	(CI),	for	which	the	
1-log	transformation	still	applies
F I G U R E  3  Secondary	sleep	outcomes	for	the	patients	included	in	the	ANCOVA	analysis.	For	the	outcomes	wake	after	sleep	onset	
(WASO),	wake	bouts,	sleep	fragmentation	index	(SFI)	and	total	sleep,	the	means	were	1-log	transformed	for	the	analysis	and	retransformed	
for	the	figure,	whereas	the	95%	confidence	intervals	(Cis)	are	still	1-log	transformed
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naturalistic,	 except	 for	 the	 interventions,	 which	 indicates	 that	 the	
treating	doctors	regarded	sleep	as	less	of	a	problem	for	the	BB	group.	
We	 regard	 the	 less	 intensive	 pharmacological	 treatment	 for	 the	BB	
group as a very important and clinically relevant observation.
Light	at	night	may	interfere	with	sleep	through	several	mecha-
nisms.	The	original	two-process	model	of	sleep	regulation	describes	
two independent synergistic processes regulating sleep propensity 
(Borbely,	 1982).	 Process	 S	describes	 the	homeostatic	 build-up	of	
sleep debt during wake. Process C refers to the circadian rhythm 
component	 (Borbely,	 1982).	 This	 model	 still	 holds	 ground,	 but	
the original model of two independent factors has recently been 
revised	 (Xu	 &	 Lang,	 2018).	 New	 research	 has	 revealed	 multiple	




12 p.m. 6 p.m. 12a.m.                     6 a.m. 12 p.m.                           6 p.m. 12 a.m. 6 a.m.
(a) Three actograms from placebo group (b) Three actograms from BB group
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reciprocal interactions between these two processes; examples 






In	 modern	 society,	 light	 exposure	 is	 a	 concomitant	 of	 wake-
fulness. Picture a manic patient waking up at 03:00 hours feeling 
rested. This patient will surely not stay in bed in a dark room but 
rather reach for the light switch and suddenly feel even more awake 
and	 energetic.	 In	 this	 example,	 wake	 and	 light	 form	 a	 reinforcing	
feedback	 loop,	 directly	 and	 rapidly	 affecting	 the	 sleep-regulation	
processes.	Short-wavelength	light	through	the	ipRGC	system	coun-
teracts	 and	withholds	 the	effects	of	 the	 sleep-promoting	 factor	S	
(sleep	depth),	through	activating	wake-promoting	projections	to	the	
hypothalamus,	 and	via	SCN-hypothalamic	and	brainstem-hypotha-
lamic	 projections	 (Hattar	 et	 al.,	 2006;	 LeGates	 et	 al.,	 2014;	 Saper	
&	Fuller,	2017).	Light	also	exerts	effects	on	factor	C,	the	circadian	







and	 thereby	 stronger	 sleep-promoting	 influence	 from	 the	 homeo-
static	 factor	 S.	 Several	 patients	 spontaneously	 reported	 a	 sudden	
awareness	of	 feeling	calm,	 tired	or	sleepy	after	putting	on	 the	BB	
glasses. Patients in a manic state are relatively sleep deprived and 
in this state may be particularly sensitive to the activating effects of 
light	(Gold	&	Sylvia,	2016;	Henriksen	et	al.,	2016).
The	previously	reported	YMRS	and	activity	data	from	the	RCT	











As	described	 in	 a	 previous	publication,	 the	 interventions	were	
visible	 to	 the	 participants	 and	 the	 nursing	 staff	 (Henriksen	 et	 al.,	
2016).	No	patients	observed	any	intervention	other	than	their	own.	
We	instructed	the	nursing	staff	to	present	a	uniform	approach	to-
wards	 the	 two	 groups;	 that	 is,	 encourage	 equally	 the	 use	 of	 the	
glasses according to the protocol. The study was undertaken before 
there was any knowledge in the patient population on the effects of 
BB	glasses,	so	we	regard	clear	glasses	as	a	valid	placebo	at	the	time	
of the data collection. The patients could choose the position of the 
Actiwatch	(left	or	right	wrist).	We	did	not	note	the	individual	choices,	
but previous studies have shown no significance of position of the 
actigraph	 regarding	 sleep	 outcomes	 (Littner,	 Kushida,	 Anderson,	
Bailey,	&	Berry,	2003).
The	sample	was	small	for	analysing	actigraphy	data,	making	the	
study	 susceptible	 to	 type	 II	 errors.	 Two	 patients	 dropped	 out	 to-
wards the end of the intervention because they were allocated to 
the	placebo	condition	and	not	to	the	BB	intervention	(worsening	of	
symptoms	and	no	subjective	effect).	This	limited	the	interpretation	
of the outcomes in the placebo group after night 5. The lack of base-
line	data	is,	however,	the	most	serious	limitation,	preventing	precise	
effect-size	calculations.	Based	on	previous	observations,	 it	 is	 likely	
that	some	effects	were	present	already	on	the	first	night	(Henriksen	
et	al.,	2014).
From	 this	 actigraphy	 study	 on	 the	 effects	 of	 BB	 glasses	 on	
sleep	as	an	adjunctive	treatment	for	mania,	we	found	that	the	BB	
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